semaglutide cardiovascular outcomes trial Beyond obesity: Novo's SELECT re-defines risk management A Skeptical Take of Semaglutide – Designing Next-Generation Cardiometabolic Outcome Trials

Understanding what you actually receive helps contextualize the pricing and compare it against other providers

Telemedicine or online pharmacy providers can have competitive pricing also, as they do not incur the same costs as a physical facility

The involvement of a licensed clinician who reviews health history before prescribing is a structural difference that OTC supplement purchases do not include

Sessions are relatively short, and downtime is minimal, making it a convenient option for many

Right now, we have excellent data for Type 2 diabetes, heart disease and obesity

GIP receptor (present in retatrutide and tirzepatide, absent in survodutide): Glucose-dependent insulinotropic polypeptide (GIP) enhances insulin secretion in a glucose-dependent manner, promotes nutrient uptake and lipid metabolism in adipose tissue, and may improve adipose tissue remodeling